Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1440]

Lung cancer immunotherapy adjuvant and neoadjuvant indications

Dr. Luis Raez - Memorial Healthcare System, Florida, USA

Lung cancer immunotherapy adjuvant and neoadjuvant indications ( Dr. Luis Raez - Memorial Healthcare System, Florida, USA )

Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial

Dr Maximilian Merz - Leipzig University, Leipzig, Germany

Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )

Study shows that there is slower cancer drug approval in Europe

Dr Mark Lythgoe - Imperial College London, London, UK

Study shows that there is slower cancer drug approval in Europe ( Dr Mark Lythgoe - Imperial College London, London, UK )

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is...

Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands

Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Glofitamab induces durable complete remissions in patients with relapsed large...

Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma ( Prof Michael Dickinson - Peter MacCallum Cancer Centre, Victoria, Australia )

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy...

Prof Barbara Eichhorst - University of Cologne, Cologne, Germany

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA

Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory...

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany

$The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )$

More from ecancer